Vés al contingut

A phase 2, multicenter, open-label study to assess appropriate dosing and to evaluate safety ofcrizanlizumab, with or without hydroxyurea/hydroxycarbamide, in sequential,descending age groups of pediatric sickle cell disease patients with vaso-occlusive crisis.

Obert
  • Codi protocol: CSEG101B2201
  • Codi EudraCT: 2017-001747-12
  • Grup de recerca: Càncer i Malalties Hematològiques Infantils
  • Servei: Oncohematologia Pediàtrica
  • Investigador/a principal:  Díaz de Heredia Rubio, Maria Cristina
  • Fase: Fase II
  • Estat reclutament: Reclutant voluntaris